| Characteristics . | Evaluation Cohort(n = 127) . | Validation Cohort (n = 59) . |
|---|---|---|
| Age, y | 30 (25–35) | 36 (30–43) |
| Male sex | 92 (72.4) | 46 (78.0) |
| HBV genotype | ||
| B | 55 (43.3) | NA |
| C | 72 (56.7) | NA |
| HBsAg level at EOT, log10 IU/mL | 3.3 (2.9–3.7) | 2.6 (1.4–3.0) |
| < 2 log10 IU/mL | 11 (8.7) | 22 (37.3) |
| HBcrAg level at EOT, log10 U/mL | 4.3 (4.0–4.7) | 3.9 (3.3–4.5) |
| < 4 log10 U/mL | 30 (23.6) | 31 (52.5) |
| HBV RNA level at EOT, log10 copies/mL | 3.0 (0–3.2) | 3.8 (0–4.5) |
| Negative HBV RNA | 40 (31.5) | 21 (35.6) |
| Negative HBV DNA at EOTa | 62 (48.8) | 43 (72.9) |
| Treatment duration, y | 2.9 (2.1–3.9) | 4.5 (3.2–6.0) |
| Consolidation treatment durationb, y | 1.5 (1.2–2.1) | 2.4 (1.3–3.5) |
| Characteristics . | Evaluation Cohort(n = 127) . | Validation Cohort (n = 59) . |
|---|---|---|
| Age, y | 30 (25–35) | 36 (30–43) |
| Male sex | 92 (72.4) | 46 (78.0) |
| HBV genotype | ||
| B | 55 (43.3) | NA |
| C | 72 (56.7) | NA |
| HBsAg level at EOT, log10 IU/mL | 3.3 (2.9–3.7) | 2.6 (1.4–3.0) |
| < 2 log10 IU/mL | 11 (8.7) | 22 (37.3) |
| HBcrAg level at EOT, log10 U/mL | 4.3 (4.0–4.7) | 3.9 (3.3–4.5) |
| < 4 log10 U/mL | 30 (23.6) | 31 (52.5) |
| HBV RNA level at EOT, log10 copies/mL | 3.0 (0–3.2) | 3.8 (0–4.5) |
| Negative HBV RNA | 40 (31.5) | 21 (35.6) |
| Negative HBV DNA at EOTa | 62 (48.8) | 43 (72.9) |
| Treatment duration, y | 2.9 (2.1–3.9) | 4.5 (3.2–6.0) |
| Consolidation treatment durationb, y | 1.5 (1.2–2.1) | 2.4 (1.3–3.5) |
Categorical variables are expressed as counts (percentage). Continuous variables are expressed as median values (interquartile range).
Abbreviations: ALT, alanine aminotransferase; EOT, end of treatment; HBsAg, hepatitis B surface antigen; HBcrAg, hepatitis B core–related antigen; HBV, hepatitis B virus; NA, not available; ULN, upper limit of normal.
aNegative HBV DNA was defined as HBV DNA “target not detected.”
bConsolidation treatment duration was defined as the treatment duration after achieving HBV DNA < 50 IU/mL and hepatitis B e antigen seroconversion.
| Characteristics . | Evaluation Cohort(n = 127) . | Validation Cohort (n = 59) . |
|---|---|---|
| Age, y | 30 (25–35) | 36 (30–43) |
| Male sex | 92 (72.4) | 46 (78.0) |
| HBV genotype | ||
| B | 55 (43.3) | NA |
| C | 72 (56.7) | NA |
| HBsAg level at EOT, log10 IU/mL | 3.3 (2.9–3.7) | 2.6 (1.4–3.0) |
| < 2 log10 IU/mL | 11 (8.7) | 22 (37.3) |
| HBcrAg level at EOT, log10 U/mL | 4.3 (4.0–4.7) | 3.9 (3.3–4.5) |
| < 4 log10 U/mL | 30 (23.6) | 31 (52.5) |
| HBV RNA level at EOT, log10 copies/mL | 3.0 (0–3.2) | 3.8 (0–4.5) |
| Negative HBV RNA | 40 (31.5) | 21 (35.6) |
| Negative HBV DNA at EOTa | 62 (48.8) | 43 (72.9) |
| Treatment duration, y | 2.9 (2.1–3.9) | 4.5 (3.2–6.0) |
| Consolidation treatment durationb, y | 1.5 (1.2–2.1) | 2.4 (1.3–3.5) |
| Characteristics . | Evaluation Cohort(n = 127) . | Validation Cohort (n = 59) . |
|---|---|---|
| Age, y | 30 (25–35) | 36 (30–43) |
| Male sex | 92 (72.4) | 46 (78.0) |
| HBV genotype | ||
| B | 55 (43.3) | NA |
| C | 72 (56.7) | NA |
| HBsAg level at EOT, log10 IU/mL | 3.3 (2.9–3.7) | 2.6 (1.4–3.0) |
| < 2 log10 IU/mL | 11 (8.7) | 22 (37.3) |
| HBcrAg level at EOT, log10 U/mL | 4.3 (4.0–4.7) | 3.9 (3.3–4.5) |
| < 4 log10 U/mL | 30 (23.6) | 31 (52.5) |
| HBV RNA level at EOT, log10 copies/mL | 3.0 (0–3.2) | 3.8 (0–4.5) |
| Negative HBV RNA | 40 (31.5) | 21 (35.6) |
| Negative HBV DNA at EOTa | 62 (48.8) | 43 (72.9) |
| Treatment duration, y | 2.9 (2.1–3.9) | 4.5 (3.2–6.0) |
| Consolidation treatment durationb, y | 1.5 (1.2–2.1) | 2.4 (1.3–3.5) |
Categorical variables are expressed as counts (percentage). Continuous variables are expressed as median values (interquartile range).
Abbreviations: ALT, alanine aminotransferase; EOT, end of treatment; HBsAg, hepatitis B surface antigen; HBcrAg, hepatitis B core–related antigen; HBV, hepatitis B virus; NA, not available; ULN, upper limit of normal.
aNegative HBV DNA was defined as HBV DNA “target not detected.”
bConsolidation treatment duration was defined as the treatment duration after achieving HBV DNA < 50 IU/mL and hepatitis B e antigen seroconversion.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
